Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants

ABSTRACT

Known cyclic amino acids, such as gabapentin and pregabalin, are used for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants and other addictive drugs/substances. Physiological conditions include stimulant-induced toxicities.

This application claims benefit to U.S. provisional application Ser. No.60/056,189, filed Aug. 19, 1997.

FIELD OF THE INVENTION

The present invention relates to novel therapeutic uses of a knowncompound, gabapentin, its derivatives, and pharmaceutically acceptablesalts. The present invention concerns a method for treatingphysiological conditions associated with the use, or sequelae of use, ofcocaine or other addictive drugs/substances in a mammal in need of suchtreatment.

BACKGROUND OF THE INVENTION

Cocaine abuse and addiction have increased greatly during the lastdecade. Cocaine is a member of the class of drugs known as psychomotorstimulants. The term “psychomotor stimulants” refers to a class of drugsthat stimulates a mammal's central nervous system. Examples ofpsychomotor stimulants include, but are not limited to amphetamine,methamphetamine, methylphenidate, and other agents with similarpharmacological actions.

Often the use, or sequelae of use, of cocaine or other psychomotorstimulants is associated with psychopathological conditions. Thepsychopathological conditions of cocaine and other psychomotorstimulants are generally similar, or in some cases identical. Craving,dysphoria, and depression are important components of withdrawalsyndromes from cocaine and psychomotor stimulants other than cocaine.

In animals, repeated exposure to cocaine can induce supersensitivity tomany of its effects including seizures, behavioral hyperactivity, andstereotypy. The development of supersensitivity to the convulsanteffects of cocaine following repeated exposures is similar in somerespects to the phenomenon known as kindling, the reduction of seizurethreshold after repeated electrical stimulation of certain brainregions. The brain regions in which kindling is obtained includeportions of the limbic system, areas of the brain believed to beinvolved in normal emotional behaviors, as well as somepsychopathological behaviors (eg, Post et al, 1972). Thus, it has beensuggested that a kindling-like phenomenon may be involved in thedevelopment of cocaine addiction and craving.

U.S. Pat. No. 4,024,175, its divisional U.S. Pat. No. 4,087,544, andU.S. Pat. No. 5,563,175 cover the compounds of the instant invention,methods for preparing them, and several uses thereof. The uses disclosedare: protective effect against cramp induced by thiosemicarbazide;protective action against cardiazole cramp; the cerebral diseasesepilepsy, faintness attacks, hypokinesia, and cranial traumas; andimprovement in cerebral functions. The compounds are useful in geriatricpatients.

U.S. Pat. Nos. 5,025,035 and 5,084,479 also disclose methods for usingthe compounds of the instant invention. U.S. Pat. No. 5,025,035discloses methods of treating depression. U.S. Pat. No. 5,084,479discloses methods for treating neurodegenerative diseases. The patentsare hereby incorporated by reference.

There is no disclosure in the above references to suggest the presentinventions uses of compounds of U.S. Pat. No. 4,024,175, its divisionalU.S. Pat. No. 4,087,544, and U.S. Pat. No. 5,563,175 to treatphysiological conditions associated with the use, or sequelae of use, ofcocaine or other addictive agents.

SUMMARY OF THE INVENTION

To the extent that kindling-like phenomena are involved, it has beendiscovered that gabapentin, its derivatives and pharmaceuticallyacceptable salts, will be effective in treating not only seizures, butalso physiological abnormalities or toxicities caused by repeatedexposure to cocaine and/or other psychomotor stimulants.

It has also been discovered that gabapentin, its derivatives, andpharmaceutically acceptable salts will be effective in treatingphysiological conditions caused by repeated exposure to addictivedrugs/substances other than cocaine.

There have been various reports that provide functional andneurochemical evidence that there are specific neurobiologicalcommonalties between addictive drugs/substances. Dopamineneurotransmission in the mesolimbic system, and particularly in thenucleus accumbens, is currently recognized as a critical target of drugsof abuse (Wise R. A. and Bozarth M. A., Psychol. Rev., 1987;94:469-492;Koob G. F., Trends Pharmacol. Sci., 1992;13:177-184; Di Chiara G., DrugAlcohol Depend., 1995;38:95-121). Among drugs active in the centralnervous system, the ability to act as a rewarding stimulus, to activatemotor behavior, and to increase synaptic dopamine concentrations in themesolimbic system are in some way linked. Drugs that are abused are fromdiverse classes (depressants, stimulants, nicotine, opiates, heroin,barbiturates, hallucinogens, sedative/hypnotics, solvents, steroids)suggesting that they might act through a common mediator. It has beendetermined that drugs abused by humans stimulate doparnine transmissionin the nucleus accumbens while drugs with aversive properties reduceddopamine release and drugs not abused by humans failed to modifysynaptic dopamine concentrations (Di Chiara G. and Imperato A., Proc.Natl. Acad. Sci., 1988;85:5274-5278). It has been discovered thatsuccessful treatment of a psychostimulant-induced physiologicalcondition with gabapentin, its derivatives, and pharmaceuticallyacceptable salts can be extended to treating the physiologicalconditions of drugs of abuse other than cocaine and other psychomotorstimulants.

In one embodiment, the present invention discloses a method for treatingphysiological conditions associated with the use, or sequelae of use, ofpsychomotor stimulants such as cocaine and other abuseddrugs/substances. The present invention comprises administering atherapeutically effective amount of a compound of Formula I:

wherein R₁ is hydrogen or a lower alkyl and n is 4, 5, or 6 or apharmaceutically acceptable salt thereof, in unit dosage form, to amammal in need of said treatment. Preferably, it has been found that theadministration of gabapentin is effective in treating physiologicalconditions associated with the use, or sequelae of use, of psychomotorstimulants and other addictive drugs/substances.

In another preferred embodiment, the present invention comprisesadministering a therapeutically effective amount of a compound ofFormula II:

wherein R₁₁ is a straight or branched alkyl of from 1 to 6 carbon atoms,phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₁₂ is hydrogenor methyl; and R₁₃ is hydrogen, methyl, or carboxyl; or an individualenantiomeric isomer thereof; or a pharmaceutically acceptable saltthereof, in unit dosage form, to a mammal in need of said treatment.Preferably, it has been found that the administration ofpregabalin((S)-3-(aminoethyl)-5-methylhexanoic acid) is effective intreating physiological conditions associated with the use, or sequelaeof use, of psychomotor stimulants and other addictive drugs/substances.

The term “physiological conditions” associated with the use, or sequelaeof use, of psychomotor stimulants or other addictive drugs/substances ismeant to cover a broad number of pathological states. Nonlimitingexamples of pathological states include tachycardia, hypertension,mydriasis and agitation, death may be caused by a cardiovascularcollapse or respiratory failure, viral hepatitis intracranialhemorrhages, cardiac arrhythmias secondary to hypertension, necrotizingangitits, fever, leukemoid reaction, disseminated intravascularcoagulation, rhabdomyolysis, and acute renal failure. A number of otherpathophysiological conditions that can be treated by the methods of thepresent invention are referenced in “The Pathology of Drug Abuse”,Steven B. Karch, 1993, CRC Press, Inc.

The term “addictive drugs/substances” is meant to cover drugs/substancesother than psychomotor stimulants that are abused, and preferably thosedrugs/substances that target dopamine neurotransmission. Addictivedrugs/substances include but are not limited to depressants, nicotine,opiates, heroin, barbiturates, hallucinogens, sedative/hypnotics,solvents, steroids. Specific non-limiting examples of addictivedrugs/substances include alfentanyl, alphaprodine, anileridine,bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmorphine,fentanyl, heroin, hydrocodone, hydromorphone, isomethadone,levomethorphan, morphine, meperidine, phenomorphan, phenoperidine,piritradide, pholcodine, proheptazoine, properidine, propiran,racemoramide, thebacon, trimeperidine, and the pharmaceuticallyacceptable salts thereof.

BRIEF DESCRIPTION OF THE DRAWINGS

In order that the manner in which the above-recited and other advantagesand objects of the invention are obtained, a more particular descriptionof the invention briefly described above will be rendered by referenceto specific embodiments thereof which are illustrated in the appendeddrawings. Understanding that these drawings depict only typicalembodiments of the invention and are therefore not to be consideredlimiting of its scope, the invention will be described with additionalspecificity and detail through the use of the accompanying drawings inwhich:

FIG. 1 demonstrates how gabapentin dose dependently blockedcocaine-stimulated increase in locomotor activity in rats.

FIG. 2 demonstrates how gabapentin dose dependently blockedamphetamine-stimulated increase in locomotor activity in rats.

FIG. 3 demonstrates how pregabalin dose dependently blockedcocaine-stimulated increase in locomotor activity in rats.

FIG. 4 demonstrates pregabalin dose dependently blockedamphetamine-stimulated increase in locomotor activity in rats.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to novel methods of treating physiologicalconditions associated with the use, or sequelae of use, of cocaine orother psychomotor stimulants and other addictive drugs/substances in amammal in need of such treatment. The treatment comprises administeringin unit dosage form an effective amount of a compound of Formula I:

wherein R₁ is hydrogen or a lower alkyl and n is 4, 5, or 6 or apharmaceutically acceptable salt thereof, in unit dosage form, to amammal in need of said treatment. The term lower alkyl includes straightor branched chain alkyl groups of up to 8 carbon atoms.

Preferred compounds of Formula I above include but are not limited to1-aminomethyl-1-cyclohexane-acetic acid, ethyl1-aminomethyl-1-cyclohexaneacetate, 1-aminomethyl-1-cycloheptane-aceticacid, 1-aminomethyl-1-cyclopentane-acetic acid, methyl1-aminomethyl-1-cyclohexane-acetate, n-butyl1-aminomethyl-1-cyclohexane-acetate, methyl1-aminomethyl-1-cycloheptaneacetate, n-butyl1-aminomethyl-1-cycloheptane-acetate, toluene sulfonate,1-aminomethyl-1-cyclopentane-acetate, benzene-sulfonate, and n-butyl1-aminomethyl-1-cyclopentane-acetate.

The most preferred compound is 1-aminomethyl-cyclohexane acetic acid(gabapentin).

In another preferred embodiment, the present invention comprisesadministering a therapeutically effective amount of a compound ofFormula II:

wherein R₁₁ is a straight or branched alkyl of from 1 to 6 carbon atoms,phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₁₂ is hydrogenor methyl; and R₁₃ is hydrogen, methyl, or carboxyl; or an individualenantiomeric isomer thereof; or a pharmaceutically acceptable saltthereof, in unit dosage form, to a mammal in need of said treatment. Thepreferred compound of Formula II is pregabalin.

Pharmaceutical compositions of the compound of the present invention orits salts are produced by formulating the active compound in dosage unitform with a pharmaceutical carrier. Some examples of dosage unit formsare tablets, capsules, pills, powders, aqueous and nonaqueous oralsolutions and suspensions, and parenteral solutions packaged incontainers containing either one or some larger number of dosage unitsand capable of being subdivided into individual doses. Some examples ofsuitable pharmaceutical carriers, including pharmaceutical diluents, aregelatin capsules; sugars such as lactose and sucrose; starches such ascorn starch and potato starch, cellulose derivatives such as sodiumcarboxymethyl cellulose, ethyl cellulose, methyl cellulose, andcellulose acetate phthalate; gelatin; talc; stearic acid; magnesiumstearate; vegetable oils such as peanut oil, cottonseed oil; sesame oil,olive oil, corn oil, and oil of theobroma; propylene glycol, glycerin;sorbitol; polyethylene glycol; water; agar; alginic acid; isotonicsaline, and phosphate buffer solutions; as well as other compatiblesubstances normally used in pharmaceutical formulations. Thecompositions of the invention can also contain other components such ascoloring agents, flavoring agents, and/or preservatives. Thesematerials, if present, are usually used in relatively small amounts. Thecompositions can, if desired, also contain other therapeutic agents.

The percentage of the active ingredient in the foregoing compositionscan be varied within wide limits, but for practical purposes it ispreferably present in a concentration of at least 10% in a solidcomposition and at last 2% in a primary liquid composition. The mostsatisfactory compositions are those in which a much higher proportion ofthe active ingredient is present.

The method of administration of the pharmacotherapies may vary. For themost part, however, routes of administration of the subject compound orits salts are oral or parenteral. For example, a useful intravenous doseis between 5 and 50 mg and a useful oral dosage is between 20 and 200mg. The exact individual dosage, as well as the daily dosage, will bedetermined according to standard principles under the direction of aphysician.

As noted, gabapentin is recognized as a particularly effectivepharmacotherapy for use in the subject method, gabapentin will typicallybe administered as an injectable, capsule, or tablet. Preparation ofthese gabapentin containing dosage forms are as follows:

Injectables, 1 mg to 100 mg/mL

Gabapentin

Water for Injection USP q.s.

The compound or a suitable salt thereof is dissolved in water and passedthrough a 0.2-micron filter. Aliquots of the filtered solution are addedto ampoules or vials, sealed, and sterilized.

Capsules, 50, 100, 200, 300, or 400 mg

Gabapentin, 250 g

Lactose USP, Anhydrous q.s. or 250 g

Sterotex Powder HM, 5 g

Combine the compound and the lactose in a tumble blend for 2 minutes,blend for 1 minute with the intensifier bar, and then tumble blend againfor 1 minute. A portion of the bend is then mixed with the Sterotexpowder, passed through a No. 30 screen, and added back to the remainderof the blend. The mixed ingredients are then blended for 1 minute,blended with the intensifier bar for 30 seconds, and tumble blended foran additional minute. The appropriately sized capsules are filled with141, 352.5, or 705 mg of the blend, respectively, for the 50, 125, and250 mg containing capsules.

Tablets, 5, 100, 200, 300, 400, 500, or 600 mg

Gabapentin, 125 g

Corn Starch NF, 200 g

Cellulose, Microcrystalline, 46 g

Sterotex Powder HM, 4 g

Purified Water q.s. or 300 mL

Combine the corn starch, the cellulose, and the compound together in aplanetary mixer and mix for 2 minutes. Add the water to this combinationand mix for 1 minute. The resulting mix is spread on trays and dried ina hot air oven at 500° C. until a moisture level of 1% to 2% isobtained. The dried mix is then milled with a Fitzmill through a No.RH2B screen and added back to the milled mixture, and the total blendedfor 5 minutes by drum rolling. Compressed tablets of 150, 375, and 750mg, respectively, of the total mix are formed with appropriate sizedpunches the 50, 125, or 50 mg containing tablets.

A unit dosage form of the instant invention may also comprise othercompounds useful in the therapy of neurodegenerative diseases.

The advantages of using the compounds of Formulas I and II, especiallygabapentin, in the instant invention include the relatively nontoxicnature of the compound, the ease of preparation, the fact that thecompound is well-tolerated, and the ease of IV administration of thedrug. Further, the drug is not metabolized in the body.

The subjects as used herein are mammals, including humans.

The above disclosure generally describes the present invention. A morecomplete understanding can be obtained by reference to the followingspecific examples which are provided herein for purposes of illustrationonly and are not intended to be limiting unless otherwise specified.

The usefulness of compounds of Formulas I and II above, and the saltsthereof as agents for treating physiological conditions associated withthe use, or sequelae of use, of cocaine or other psychomotor stimulantsand other addictive drugs/substances is demonstrated in standardpharmacological test procedures. Examples of standard pharmacologicaltest procedures include, but are not limited to locomotor activity,intravenous drug self-administration in rodents or primates, conditionedplace preference tests, and drug discrimination.

EXAMPLE 1

In this example, gabapentin and pregabalin were administered to ratstreated with psychostimulants to determine their anti-abuse andanti-addictive potential. The effects of compounds on locomotor activityof rodents are predictive of their therapeutic anti-abuse oranti-addictive properties. The administration of cocaine (an abuseagent) or amphetamine result in increase in locomotor activity of rats,and these results were dose-dependently blocked by gabapentin andpregabalin (see FIGS. 1-4).

Description of Locomotor Activity. Test Paradigm:

Locomotor Activity

Male Sprague-Dawley rats from Harlan labs (200-275 g) were used for alllocomotor activity studies. Locomotor activity data (expressed asdistance traveled in cm) was measured in the Omnitech Digiscan animalactivity monitors. Twenty-four Omnitech chambers were used in eachstudy, each consisting of a 16′×16′ square plexiglas open field with 2sets of 16 infrared photobeams assembled on each of the four sides ofthe apparatus.

1. Test Name: Spontaneous locomotor activity in rats

 Test Rationale: To determine the effects of compound oncocaine-stimulated locomotor activity

Cocaine Interaction Study:

Rats were given saline or test drug IP 45 minutes prior to an IP salineor cocaine injection (10 mg/kg IP). Rats were then placed in separateOmnitech chambers for an additional 15-minute drug absorption period (indark), after which time locomotor activity was measured for 1 hour (indark). Data were expressed as distance traveled (in cm).

2. Test Name: Spontaneous locomotor activity in rats

 Test Rationale: To determine the effects of compound onamphetamine-stimulated locomotor activity

Amphetamine Interaction Study:

Rats were given saline or test drug and placed in Omnitech chambers foran additional 15 minutes (in dark) prior to an IP saline ord-amphetamine injection (0.5 mg/kg IP). Rats were returned to theirrespective chamber for a 15-minute drug absorption period, after whichtime locomotor activity was measured for 30 minutes (in dark). Data wereexpressed as distance traveled (in cm) N-4-5 rats per group.

What is claimed is:
 1. A method for treating physiological conditionsassociated with the use, or sequelae of use, of psychomotor stimulantswhich comprises administering a therapeutically effective amount of acompound of Formula II:

wherein R₁₁ is a straight or branched alkyl of from 1 to 6 carbon atoms,phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₁₂ is hydrogenor methyl; and R₁₃ is hydrogen, methyl, or carboxyl; or an individualenantiomeric isomer thereof; or a pharmaceutically acceptable saltthereof, in unit dosage form, to a mammal in need of said treatment. 2.A method according to claim 1, wherein the psychomotor stimulant iscocaine.
 3. A method according to claim 1, wherein the psychomotorstimulant is amphetamine.
 4. A method according to claim 1, wherein thephysiological condition is stimulant-induced toxicities.
 5. A methodaccording to claim 1, wherein the compound is(S)-3-(aminomethyl)-5-methylhexanoic acid or a pharmaceuticallyacceptable salt thereof.
 6. A method according to claim 1, wherein anindividual dose is 5 to 50 mg parenterally or 20 to 200 mg enterally ofthe compound or a pharmaceutically acceptable salt thereof isadministered.
 7. A method for treating physiological conditionsassociated with the use, or sequelae of use, of addictivedrugs/substances which comprises administering a therapeuticallyeffective amount of a compound of Formula II:

wherein R₁₁ is a straight or branched alkyl of from 1 to 6 carbon atoms,phenyl, or cycloalkyl having from 3 to 6 carbon atoms; R₁₂ is hydrogenor methyl; and R₁₃ is hydrogen, methyl, or carboxyl; or an individualenantiomeric isomer thereof; or a pharmaceutically acceptable saltthereof, in unit dosage form, to a mammal in need of said treatment. 8.A method according to claim 7, wherein the addictive drug/substance isnicotine.
 9. A method according to claim 7, wherein the addictivedrug/substance is an opiate.
 10. A method according to claim 7, whereinthe physiological condition is stimulant-induced toxicities.
 11. Amethod according to claim 7, wherein the compound is(S)-3-(aminomethyl)-5-methylhexanoic acid or a pharmaceuticallyacceptable salt thereof.
 12. A method according to claim 7, wherein anindividual dose is 5 to 50 mg parenterally or 20 to 200 mg enterally ofthe compound or a pharmaceutically acceptable salt thereof isadministered.